Omega-3 Deficiency and Cardiac Events

The American Heart Association released a scientific statement in 2002 acknowledging that the dietary consumption of Omega-3 polyunsaturated fatty acids reduces the incidence of cardiovascular disease. – Kris-Etherton 2002; Circulation

Blood levels of long-chain Omega-3 polyunsaturated fatty acids have been shown to be strongly associated with a reduced risk of sudden death in apparently healthy males. – Albert, 2007; New England Journal of Medicine

Prospective randomized intervention studies have shown that dietary supplementation with two Omega-3 polyunsaturated fatty acids, namely EPA and DHA, significantly reduces the risk of death, recurrent nonfatal myocardial infarction or stroke in patients who have already suffered a myocardial infarction.

Randomized placebo-controlled studies have also shown that dietary supplementation with either EPA or DHA alone significantly increased blood levels of Omega-3 polyunsaturated fatty acids and significantly reduced blood triglyceride levels, both in mildly hyperlipidemic males and apparently healthy males – Mori, 2000 & Grimsgard 1997; American Journal of Clinical Nutrition

Dietary supplementation with EPA and DHA is also generally well-tolerated, with few side effects.

VASCAZEN^TM is intended for the dietary management of cardiovascular disease, in patients deficient in Omega-3 and raises EPA and DHA to levels associated with cardioprotection, and prevention of sudden cardiac death.

*Kris-Etherton PM, Harris WS, Appel LJ, et. al.:  Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease.  Circulation 2002 106; 2747-57

*Albert CM, Campos H, Stampfer MJ, et al.: Blood levels of long- chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113–1118.

*Kris-Etherton PM, Shaffer Taylor D, Yu-Poth S, et. al.:  Polyunsaturated fatty acids in the food chain in the United States.  Am. J. Clin. Nutr. 2000;71(suppl)179S-88S